Editorial Board ::: Current Radiopharmaceuticals

ISSN: 1874-4729 (Online)
ISSN: 1874-4710 (Print)


Volume 9, 3 Issues, 2016


Download PDF Flyer




Current Radiopharmaceuticals

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Sean L. Kitson
Current Radiopharmaceuticals
Radiochemistry
Almac Sciences
Almac House
20 Seagoe Industrial Estate
Craigavon, BT63 5QD
Northern Ireland


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Sean L. Kitson
Current Radiopharmaceuticals
Radiochemistry
Almac Sciences
Almac House
20 Seagoe Industrial Estate
Craigavon, BT63 5QD
Northern Ireland



Co-Editor(s):

Luigi Mansi
Second University of Naples
Naples
Italy


Associate Editor(s):

G.L. Cascini
University of Catanzaro
Catanzaro
Italy

F. Dollé
CEA, Institut d'imagerie biomédicale
Service Hospitalier Frédéric Joliot
Orsay
France

J. Kunikowska
Medical University of Warsaw
Warsaw
Poland

A. Ciarmiello
S. Andrea Hospital
La Spezia
Italy

P.A. Erba
University of Pisa Medical School
Pisa
Italy

M. Marengo
University of Bologna
Bologna
Italy

V. Cuccurullo
Second University of Naples
Naples
Italy

L. Evangelista
Radiotherapy and Nuclear Medicine Unit
Padova
Italy

D. Piciu
Institute of Oncology "Prof.Dr.Ion Chiricuta"
Cluj-Napoca
Romania


Regional Editor(s):

F.F. (Russ) Knapp
Emeritus Corporate Research Fellow
Oak Ridge National Laboratory (ORNL)
Oak Ridge
Russia

S. Balogova
Comenius University & St Elisabeth oncologic institute
Bratislava
Slovakia

V. Rangarajan
Tata Memorial Centre
Mumbai
India

U. Ackermann
Austin Health, Heidelberg
Narre Warren
Australia

J. Cerci
Quanta Diagnóstico e Terapia
Curitiba
Brasil

N. Avril
University Hospitals Case Medical Center
Cleveland, OH
USA

R. N. Krasikova
N.P. Bechtereva Institute of the Human Brain
Saint Petersburg
Russia


Editorial Board Members:

F. Aigbirhio
University of Cambridge
Cambridge
UK

F. Bertagna
University of Brescia
Brescia
Italy

R.T. Brown
Almac Sciences
Craigavon
Northern Ireland

M. Chinol
European Institute of Oncology
Milano
Italy

A. Duatti
International Atomic Energy Agency
Vienna
Austria

P.K. Garg
Wake Forest University Health Sciences
Winston Salem, NC
USA

V. Gottumukkala
Eckert & Ziegler Eurotope
Hopkinton, MA
USA

G. Hao
UT Southwestern Medical Center
TX
USA

H. Huang
Yale University
New Haven, CT
USA

M. Kassiou
University of Sydney
Camperdown
Australia

J. Knuuti
Turku PET Centre
Turku
Finland

R.H. Larsen (Biography
R.H. Larsen

Dr. Roy H. Larsen has a Ph.D. and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo, Norway and Duke University, USA, respectively. Dr. Larsen was the main inventor in and founder of Algeta ASA (founded in 1997, acquired by Bayer AG in 2014), and he served as Managing Director and later Chief Scientific Officer in Algeta ASA from 1997-2006, He was a inventor in and founder of Nordic Nanovector ASA (2009), and Oncoinvent AS (2010). Dr. Larsen works as a consultant, inventor, founder etc within the field of radionuclide based therapeutics. Currently affiliated with Oncoinvent AS, Oslo, Norway.

)

The Norwegian Radium Hospital
Oslo
Norway

J. Lin
Jiangsu Institute of Nuclear Medicine
Wuxi
China

A. Mahmood
Harvard Medical School
Boston, MA
USA

P.M. Mitrasinovic
University of Belgrade
Belgrade
Yugoslavia

V.W. Pike
National Institute of Mental Health
Bethesda, MD
USA

N. Ramamoorthy
International Atomic Energy Agency
Vienna
Austria

T.J. Ruth
University of British Columbia & TRIUMF
Vancouver, BC
Canada

P. Scott
University of Michigan Medical School
MI
USA

M. Spadafora
S.G. Moscati Hospital
Avellino
Italy

J. Steinbach
Forschungszentrum Dresden-Rossendorf
Dresden
Germany

G. Treglia
Oncology Institute of Southern Switzerland
Bellinzona
Switzerland

A.D. Windhorst
VU University Medical Center
Amsterdam
The Netherlands

N. Belcari
University of Pisa and INFN Pisa
Pisa
Italy

P. Blower
King’s College London
London
UK

M. Chianelli
Regina Apostolorum Hospital
Albano
Italy

O. T. DeJesus
University of Wisconsin School of Medicine and Public Health
Madison
USA

S. Fanti (Biography
S. Fanti

Prof. Stefano Fanti graduated at University of Bologna. Started working in conventional nuclear medicine in the ’90, then involved in the project of PET Unit at S.Orsola Policlinic Hospital, participating to site planning then appointed as medical director in 2002. The PET Unit at S.Orsola is now recognized as one of the most active in Europe; in particular known for the nonFDG scans, in both clinical routine and research area.

At present he is full time employed in Nuclear Medicine as Professor of Diagnostic Imaging as well as Director of Nuclear Medicine Division at the S.Orsola Hospital in Bologna. Author of more than 320 full articles published in peer reviewed international journals, several books and chapters; invited lecturer at more than 120 national and international meetings.

)

University of Bologna
Bologna
Italy

V. Garibotto
Geneva University and Geneva University Hospitals
Geneva
Switzerland

B. Guérin
Université de Sherbrooke
Québec
Canada

J.Z. Ho
Merck & Co., Inc.
New Jersey, NJ
USA

S.J. Hughes
Royal Victoria Hospital
Belfast, Northern Ireland
UK

A.I. Kassis
Harvard Medical School
Boston, MA
USA

P. Kumar
Department of Oncology, University of Alberta
Edmonton, AB T6G 1Z2
Canada

J-H. Lee
National Institutes of Health
Maryland
USA

J. Link
University of Washington
Seattle, WA
USA

P. Mapelli
Imperial College London
London
UK

C. Nanni
Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi
Bologna
Italy

M.R.A. Pillai
Bhabha Atomic Research Centre
Mumbai
India

P.F. Rambaldi
Second University of Naples
Naples
Italy

H. Saji
Kyoto University
Kyoto
Japan

S. Sestini
Misericordia and Dolce Hospital
Prato
Italy

M. Sperrin
Royal Berkshire Hospital
Reading
UK

G. Tang
Xi'an Jiaotong University
Xi'an
China

G. Vaidyanathan (Biography
G. Vaidyanathan

Ganesan Vaidyanathan received his B.Sc (1973) and M.Sc (1975) in Chemistry from the University of Calicut, India and Ph.D. in Organic Chemistry from the University of Kentucky (1987). Since 1989 he is working in the Nuclear Medicine division, Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA. He is also a faculty of the Medical Physics Graduate Program at Duke. His research interests include the development of 18F-, radioiodine-, 211At-, and 177Lu-labeled radiopharmaceuticals for cancer diagnosis and therapy. He has 105 peer-reviewed publications to his credit.

)

Duke University Medical Center
Durham, NC
USA

T. Wirth
Cardiff University
Cardiff
UK

K. Bergström (Biography
K. Bergström

Dr. Bergström is a Chief Radiochemist at Helsinki University Central Hospital. He has 20+ years of experience in research developing molecular imaging tracers and methods. In 2007-2010, he served as CEO of Imanext Ltd, a CRO company specializing in molecular imaging. Before that he worked as R&D Director at MAP Medical Technologies Oy during. Prior to this he served as Vice Chief Chemist at Kuopio University Hospital. Dr. Bergström has obtained international research experience as a post-doctoral fellow (Dept. of Neuropsychiatric Research, Karolinska Hospital, Stockholm). Dr. Bergström’s publication list consists of more than 120 peer-reviewed scientific publications. He has received scientific awards such as Timo Heiskanen Prize, Finnish Society of Nuclear Medicine and Finnish Society of Radiology (2001) and CIS Jean Debiesse Award “Nuclear Medicine”, European Association of Nuclear Medicine (1995).

)

University of Helsinki
Helsinki
Finland

S. Boschi
S.Orsola-Malpighi University Hospital
Bologna
Italy

B.B. Chin
Duke University Medical Center
Durham, NC
USA

D. Denoyer
Peter MacCallum Cancer Centre
Melbourne
Australia

M. Farsad
San Maurizio Hospital
Bolzano
Italy

A. Gee
GSK & Hammersmith Hospital
London
UK

C. Halldin
Karolinska Institutet
Stockholm
Sweden

A.G. Horti
Johns Hopkins University
Baltimore, MD
USA

K. Kairemo
International Comprehensive Cancer Center Docrates
Helsinki
Finland

G.M. Knudsen
Copenhagen University Hospital
Copenhagen
Denmark

K-J. Langen
Forschungszentrum Jülich
Jülich
Germany

J.S. Lewis
Memorial Sloan-Kettering Cancer Center
NY
USA

B. Långström
Uppsala University
Imanet
Sweden

J.M. Marti-Climent
Clínica Universidad de Navarra
Pamplona
Spain

R. Neelamegam
Massachusetts General Hospital/Harvard Medical School
MA
USA

J.P. Pouget (Biography
J.P. Pouget

Dr Jean-Pierre Pouget obtained his PhD thesis in Radiobiology in 2000 from the Curie Institute in Paris and carried-out a post-doctoral fellowship in the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then moved to Paris to the French Radiation Protection and Nuclear Safety Agency (IRSN) for 4 years where he worked on radiation casualties. After moving to Montpellier, he joined the French National Institute for Health and Medical research (INSERM) where he is now leader of the Radiobiology and Targeted Radiotherapy team at the Cancer Research Institute of Montpellier (INSERM, France). He develops new radiopharmaceuticals for cancer imaging and therapy with a special focus on radiobiology. He has published about 50 papers dealing with radiobiology and radionuclide therapy and several patents. Besides research activity, Dr Pouget is involved in teaching at the University of Montpellier.

)

IRCM
Montpellier
France

D. Roeda
Service Hospitalier Frédéric Joliot
Orsay
France

D.J. Schlyer
Brookhaven National Laboratory
Upton, NY
USA

S.V. Smith
CAMS
ANSTO, Sydney
Australia

A.C. Spivey (Biography
A.C. Spivey

Alan Spivey (http://www.imperial.ac.uk/people/a.c.spivey) has been professor of synthetic chemistry at Imperial College London since 2008. Previously, he was a lecturer then reader in the Department of Chemistry, University of Sheffield. His research encompasses the development of new reactions, synthesis of complex molecules of biomedical interest, chemical biology, medicinal chemistry including interests in PET tracers for cancer diagnosis and monitoring. omputer aided drug design (CAD), solid phase synthesis and imaging chemistry. For further details of his groups research activities see: http://www.imperial.ac.uk/spiveygroup.

)

Imperial College London
London
UK

H. Tian
University of South Florida
Tampa, FL
USA

J-L. Vanderheyden
GE Healthcare Life Sciences
Waukesha, WI
USA


Advertisement

Related Journals




Related eBooks


Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science